BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Emergency services search for five people last seen in missing Jeep - 2Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
- 3Cyber Monday 2025: Save over 70% on HBO Max with this Prime Video streaming deal
- 4See the famous winged horse Pegasus fly in the autumn night sky
- 5Antivirus Programming for Exhaustive Security
- Pick Your Favored kind of books
- Watch SpaceX launch 119 payloads to orbit from California early on March 30
- In blow to Lula, Brazil Congress revives controversial environmental bill
- Overseeing Individual budgets Successfully
- Tech Patterns 2023: 12 Advancements to Keep an eye Out For
- The most effective method to Pick the Right Old Consideration Administration: Key Contemplations
- Tech giants accused of not complying with Australian social media ban
- These are the Fastest Italian Sports Cars
- 4 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security
